Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.

Viviana Lo BuonoGiangaetano D'AleoSimona CammarotoMaria Cristina De ColaFrancesca PalmeseChiara SmortoSilvia MarinoGiuseppe VenutiEdoardo SessaCarmela RificiFrancesco Corallo

Published in: Medicina (Kaunas, Lithuania) (2022)

The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.

Keyphrases

multiple sclerosis
mild cognitive impairment
risk assessment
mass spectrometry
risk factors
combination therapy